A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objectives of the study are:
1. Evaluation of the safety profile of imatinib mesylate in patients with idiopathic
hypereosinophilic syndrome resistant or refractory to, or intolerant of, prednisone,
hydroxyurea or interferon-alpha, or untreated patients carrying the Fip1L1-PDGFRA fusion
protein.
2. Evaluation of the efficacy of imatinib mesylate in patients with idiopathic
hypereosinophilic syndrome
3. Analysis of patient's blood samples for the detection of activated kinases.